Oncology Biosimilars Market Size, Share, and Growth 2021-2022
Oncology Biosimilars Market: Strategic Insights
Oncology Biosimilars Market
-
CAGR (2023 - 2031)12.8% -
Market Size 2023
US$ 9.46 Billion -
Market Size 2031
US$ 24.71 Billion
Market Dynamics
GROWTH DRIVERS
- High cost of cancer treatments
- Growing adoption of biosimilars
FUTURE TRENDS
- Development of targeted cancer biosimilars
- Enhanced regulatory support for biosimilars
OPPORTUNITIES
- Expansion in emerging markets for oncology
- Growth in hematology oncology treatments
Key Players
- CELLTRION Inc
- Teva Pharmaceutical Industries Ltd
- Pfizer Inc
- Sandoz Group AG
- Biocon
- Amgen Inc
- Samsung Bioepis
- Coherus BioSciences
- BIOCAD
Regional Overview
- North America
- Europe
- Asia-Pacific
- South and Central America
- Middle East and Africa
Market Segmentation
Drug Class - Monoclonal Antibodies
- Granulocyte Colony-Stimulating Factor
- Erythropoiesis-Stimulating Agents
Cancer Type - Colorectal Cancer
- Cervical Cancer
- Breast Cancer
- Supportive Care
- Lymphoma
and Distribution Channel - Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Get Free Sample For